Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

Xintela: Awaiting final follow-up data - VH Corp

Xintela

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
• The 24-month follow-up data to be reported by the end of Q3
• The GMP production facility is generating revenue
• Adjusted for dilution, our fair value amounts to SEK 1.28 per share

Xintela’s half-year report did not reveal any surprises. As announced in Q1, XSTEM in knee osteoarthritis (OA) has been proven safe and tolerable by the 18-month data in all three dose levels. In Q2, the last patient in the phase I/IIa study was followed up. The complete 24-month data from the highest dose level is expected to be reported by the end of September.

Adjusted for dilution, our model suggests a fair value of SEK 1.28 per share.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.